Show simple item record

dc.contributor.authorClarke, NW
dc.contributor.authorAli, A
dc.contributor.authorIngleby, FC
dc.contributor.authorHoyle, A
dc.contributor.authorAmos, CL
dc.contributor.authorAttard, G
dc.contributor.authorBrawley, CD
dc.contributor.authorCalvert, J
dc.contributor.authorChowdhury, S
dc.contributor.authorCook, A
dc.contributor.authorCross, W
dc.contributor.authorDearnaley, DP
dc.contributor.authorDouis, H
dc.contributor.authorGilbert, D
dc.contributor.authorGillessen, S
dc.contributor.authorJones, RJ
dc.contributor.authorLangley, RE
dc.contributor.authorMacNair, A
dc.contributor.authorMalik, Z
dc.contributor.authorMason, MD
dc.contributor.authorMatheson, D
dc.contributor.authorMillman, R
dc.contributor.authorParker, CC
dc.contributor.authorRitchie, AWS
dc.contributor.authorRush, H
dc.contributor.authorRussell, JM
dc.contributor.authorBrown, J
dc.contributor.authorBeesley, S
dc.contributor.authorBirtle, A
dc.contributor.authorCapaldi, L
dc.contributor.authorGale, J
dc.contributor.authorGibbs, S
dc.contributor.authorLydon, A
dc.contributor.authorNikapota, A
dc.contributor.authorOmlin, A
dc.contributor.authorO'Sullivan, JM
dc.contributor.authorParikh, O
dc.contributor.authorProtheroe, A
dc.contributor.authorRudman, S
dc.contributor.authorSrihari, NN
dc.contributor.authorSimms, M
dc.contributor.authorTanguay, JS
dc.contributor.authorTolan, S
dc.contributor.authorWagstaff, J
dc.contributor.authorWallace, J
dc.contributor.authorWylie, J
dc.contributor.authorZarkar, A
dc.contributor.authorSydes, MR
dc.contributor.authorParmar, MKB
dc.contributor.authorJames, ND
dc.identifier.citationClarke, N. W., Ali, A., Ingleby, F. C., Hoyle, A. et al. (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial, Annals of Oncology, 30 (12), pp. 1992–2003.en
dc.identifier.pmid31987303 (pubmed)
dc.description© 2019 The Authors. Published by Elsevier. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website:
dc.description.abstractBACKGROUND:STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcomes stratified by metastatic burden for M1 patients. METHODS:We randomly allocated patients in 2 : 1 ratio to standard-of-care (SOC; control group) or SOC + docetaxel. Metastatic disease burden was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox regression models, adjusted for stratification factors, with emphasis on restricted mean survival time where hazards were non-proportional. RESULTS:Between 05 October 2005 and 31 March 2013, 1086 M1 patients were randomised to receive SOC (n = 724) or SOC + docetaxel (n = 362). Metastatic burden was assessable for 830/1086 (76%) patients; 362 (44%) had low and 468 (56%) high metastatic burden. Median follow-up was 78.2 months. There were 494 deaths on SOC (41% more than the previous report). There was good evidence of benefit of docetaxel over SOC on OS (HR = 0.81, 95% CI 0.69-0.95, P = 0.009) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P = 0.827). Analysis of other outcomes found evidence of benefit for docetaxel over SOC in failure-free survival (HR = 0.66, 95% CI 0.57-0.76, P < 0.001) and progression-free survival (HR = 0.69, 95% CI 0.59-0.81, P < 0.001) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P > 0.5 in each case). There was no evidence that docetaxel resulted in late toxicity compared with SOC: after 1 year, G3-5 toxicity was reported for 28% SOC and 27% docetaxel (in patients still on follow-up at 1 year without prior progression). CONCLUSIONS:The clinically significant benefit in survival for upfront docetaxel persists at longer follow-up, with no evidence that benefit differed by metastatic burden. We advocate that upfront docetaxel is considered for metastatic hormone naïve prostate cancer patients regardless of metastatic burden.en
dc.description.sponsorshipThis work was supported by Cancer Research UK (CRUK_A12459), Medical Research Council (MRC_MC_UU_12023/25), Astellas, Clovis Oncology, Janssen, Novartis, Pfizer and Sanofi-Aventis. Cancer Research UK CRUK_A12459 Medical Research Council MRC_MC_UU_12023/25 Astellas, Clovis Oncology, Janssen, Novartis, Pfizer and Sanofi-Aventisen
dc.subjectSTAMPEDE trialen
dc.subjecthormone naiveen
dc.subjectProstate Canceren
dc.subjectrandomised control trialen
dc.titleAddition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.en
dc.typeJournal articleen
dc.identifier.journalAnnals of Oncology : official journal of the European Society for Medical Oncologyen
dc.contributor.institutionDepartment of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester. Electronic address:
rioxxterms.funderCancer Research UK, Medical Research Council, Astellas, Clovis Oncology, Janssen, Novartis, Pfizer and Sanofi-Aventisen
dc.description.versionPublished version

Files in this item

Matheson_Addition_Of_Docetaxal ...

This item appears in the following Collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as